PART1 and hsa-miR-429-Mediated SHCBP1 Expression Is an Independent Predictor of Poor Prognosis in Glioma Patients

Abstract EN

Gliomas are the most common primary brain tumors.

Because of their high degree of malignancy, patient survival rates are unsatisfactory.

Therefore, exploring glioma biomarkers will play a key role in early diagnosis, guiding treatment, and monitoring the prognosis of gliomas.

We found two lncRNAs, six miRNAs, and nine mRNAs that were differentially expressed by analyzing genomic data of glioma patients.

The diagnostic value of mRNA expression levels in gliomas was determined by receiver operating characteristic (ROC) curve analysis.

Among the nine mRNAs, the area under the ROC curve values of only CEP55 and SHCBP1 were >0.7, specifically 0.834 and 0.816, respectively.

Additionally, CEP55 and SHCBP1 were highly expressed in glioma specimens and showed increased expression according to the glioma grade, and outcomes of high expression patients were poor.

CEP55 was enriched in the cell cycle, DNA replication, mismatch repair, and P53 signaling pathway.

SHCBP1 was enriched in the cell cycle, DNA replication, ECM receptor interaction, and P53 signaling pathway.

Age, grade, IDH status, chromosome 19/20 cogain, and SHCBP1 were independent factors for prognosis.

Our findings suggest the PART1-hsa-miR-429-SHCBP1 regulatory network plays an important role in gliomas.